Ironwood Tries To Hit for The Cyclerion With Spinoff On Deck As Spring Training Winds Down

Born as Microbia over twenty years ago, Ironwood Pharmaceuticals(IRWD) trades just 21% above its 2010 IPO price. It has managed to get to market with LINZESS, a treatment for IBS. Partnered with Allergan(AGN), LINZESS did $761.2 million in 2018 US sales. Now, Ironwood will be spinning off much of its R&D business as Cyclerion. Current Ironwood CEO and… Read More »